Bausch Health Cos EBITDA 2012-2026 | BHC
Bausch Health Cos ebitda from 2012 to 2026. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
|
Bausch Health Cos Annual EBITDA (Millions of US $) |
|
|---|---|
| 2025 | $3,115 |
| 2024 | $2,868 |
| 2023 | $2,315 |
| 2022 | $1,947 |
| 2021 | $2,057 |
| 2020 | $2,562 |
| 2019 | $1,935 |
| 2018 | $514 |
| 2017 | $3,111 |
| 2016 | $2,418 |
| 2015 | $4,139 |
| 2014 | $3,685 |
| 2013 | $1,696 |
| 2012 | $1,102 |
| 2011 | $940 |
|
Bausch Health Cos Quarterly EBITDA (Millions of US $) |
|
|---|---|
| 2026-06-30 | $1,042 |
| 2026-03-31 | $-641 |
| 2025-12-31 | $786 |
| 2025-09-30 | $941 |
| 2025-06-30 | $792 |
| 2025-03-31 | $596 |
| 2024-12-31 | $879 |
| 2024-09-30 | $653 |
| 2024-06-30 | $721 |
| 2024-03-31 | $615 |
| 2023-12-31 | $728 |
| 2023-09-30 | $343 |
| 2023-06-30 | $739 |
| 2023-03-31 | $505 |
| 2022-12-31 | $129 |
| 2022-09-30 | $601 |
| 2022-06-30 | $558 |
| 2022-03-31 | $659 |
| 2021-12-31 | $743 |
| 2021-09-30 | $973 |
| 2021-06-30 | $146 |
| 2021-03-31 | $195 |
| 2020-12-31 | $439 |
| 2020-09-30 | $909 |
| 2020-06-30 | $470 |
| 2020-03-31 | $744 |
| 2019-12-31 | $-570 |
| 2019-09-30 | $866 |
| 2019-06-30 | $803 |
| 2019-03-31 | $836 |
| 2018-12-31 | $588 |
| 2018-09-30 | $838 |
| 2018-06-30 | $560 |
| 2018-03-31 | $-1,472 |
| 2017-12-31 | $548 |
| 2017-09-30 | $770 |
| 2017-06-30 | $865 |
| 2017-03-31 | $928 |
| 2016-12-31 | $886 |
| 2016-09-30 | $-123 |
| 2016-06-30 | $837 |
| 2016-03-31 | $818 |
| 2015-12-31 | $887 |
| 2015-09-30 | $1,195 |
| 2015-06-30 | $1,069 |
| 2015-03-31 | $989 |
| 2014-12-31 | $983 |
| 2014-09-30 | $1,158 |
| 2014-06-30 | $774 |
| 2014-03-31 | $770 |
| 2013-12-31 | $653 |
| 2013-09-30 | $82 |
| 2013-06-30 | $493 |
| 2013-03-31 | $468 |
| 2012-12-31 | $237 |
| 2012-09-30 | $274 |
| 2012-06-30 | $308 |
| 2012-03-31 | $283 |
| 2011-12-31 | $211 |
| 2011-09-30 | $280 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $2.121B | $10.266B |
| Bausch Health Companies Inc. develops, manufactures and markets a wide array of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products along with medical devices such as contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices in the therapeutic areas of eye-health, gastroenterology (GI), and dermatology. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $45.423B | 17.88 |
| BridgeBio Pharma (BBIO) | United States | $13.021B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $10.175B | 25.94 |
| Aspen Pharmacare (APNHY) | South Africa | $4.248B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.445B | 20.49 |
| Personalis (PSNL) | United States | $1.717B | 0.00 |
| Taysha Gene Therapies (TSHA) | United States | $1.636B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $1.005B | 9.45 |
| Assembly Biosciences (ASMB) | United States | $0.508B | 24.48 |
| Sol-Gel Technologies (SLGL) | Israel | $0.169B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.042B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |